drugset / Trial / NCT06184269

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B"

NCT06184269

Phase 1 Completed 58 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedCrossoverDouble-blindTreatment

Summary

The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1017-1" and co-administration of "BR1017-1A" and "BR1017-1B" in healthy volunteers

Timeline

Start
2023-12-23
Primary completion
2024-02-18
Completion
2024-02-18

Drugs

EvaluationDrugModalityDoseRoute
Subject BR1017-1 Unknown
Comparator BR1017-1A Unknown
Comparator BR1017-1B Unknown